• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SAR

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Nov 19;9(12):ofac625.
doi: 10.1093/ofid/ofac625. eCollection 2022 Dec.
Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection


Nina Ekström[SUP] 1 [/SUP], Anu Haveri[SUP] 1 [/SUP], Anna Solastie[SUP] 1 [/SUP], Camilla Virta[SUP] 1 [/SUP], Pamela Österlund[SUP] 1 [/SUP], Hanna Nohynek[SUP] 2 [/SUP], Tuomo Nieminen[SUP] 3 [/SUP], Lauri Ivaska[SUP] 4 [/SUP], Paula A Tähtinen[SUP] 4 [/SUP], Johanna Lempainen[SUP] 4 5 6 [/SUP], Pinja Jalkanen[SUP] 7 [/SUP], Ilkka Julkunen[SUP] 5 7 [/SUP], Arto A Palmu[SUP] 8 [/SUP], Merit Melin[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primes the immune system; thus individuals who have recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.
Methods: We measured spike-specific immunoglobulin (Ig)G and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529/BA.1) variants following vaccination.
Results: A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and up to 4-fold higher neutralizing potency of antibodies in subjects with a previous infection compared with vaccinated subjects without a previous infection. Hybrid immunity was more enhanced after a severe than a mild infection, with sequentially decreasing NAb titers against Alpha, Beta, Delta, and Omicron variants. We found similar IgG concentrations in subjects with a previous infection after 1 or 2 vaccine doses.
Conclusions: Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.

Keywords: SARS-CoV-2; hybrid immunity; neutralizing antibodies; previous infection; variants of concern.
 
Back
Top Bottom